Fax: 2123183400

Mar 26 2009 13 CENTRAL FAX CENTER

MAR 2 6 2009

PTC/SB/26 (02-09)
Approved for use through 03/31/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional)
	NY-LUD 5253-US5-DIV
In re Application of: Thierry Boon-Falleur et al.	
Application No.: 08/819,669-Conf. #1995 Filed: March 17, 1997	
For: TUMOR REJECTION, ANTIGEN PRECURSORS, TUMOR REJECTION ANTIGEN S AND USES THEREOF	
The owner. LUDWIG INSTITUTE FOR CANCER RESEARCH of 100 percent interest in the Instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the Instant application which would extend beyond the expiration date of the full statutory term of prior patent No. 5,843,448	
as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.	
Further, the owner walves the right to separately enforce any patent granted on application 08/819,669 or any patent subject to re-examination proceedings, as well as U.S. Patent No. 5,843,448. The owner further states that any patent granted on application 09/819,669 or any patent subject to re-examination proceedings, shall be enforceable only for and during such period that the patent and U.S. Patent No. 5,843,448 are not separately owned.	
In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later.	
expires for failure to pay a maintanance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole of terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate;	
is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shorte	and he are the second
Check either box 1 or 2 below, if appropriate.	
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	
2. X The undersigned is an atterney or agent of record. Reg. No. 30,946	
	- laile
Signature	3/26/07
2 Signatore	/ Date /
Norman D. Hanson	<u></u>
Typed or printed name	
	(212) 318-3168 Telephone Number
X Charge Terminal discialmer fee under 37 CFR 1.20(d) to Credit Card, PTO Form 2038	• • • • • • • • • • • • • • • • • • • •
WARNING: Information on this form may become public. Credit card Information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (ow Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	
·	